67 related articles for article (PubMed ID: 2297734)
21. Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma.
Heiner JP; Miraldi F; Kallick S; Makley J; Neely J; Smith-Mensah WH; Cheung NK
Cancer Res; 1987 Oct; 47(20):5377-81. PubMed ID: 3115567
[TBL] [Abstract][Full Text] [Related]
22. Comparison of biodistribution of 791T/36 monoclonal antibody and its Fab/c fragment in BALB/c mice and nude mice bearing human tumor xenografts.
Demignot S; Pimm MV; Baldwin RW
Cancer Res; 1990 May; 50(10):2936-42. PubMed ID: 2334894
[TBL] [Abstract][Full Text] [Related]
23. Improved iodine radiolabels for monoclonal antibody therapy.
Stein R; Govindan SV; Mattes MJ; Chen S; Reed L; Newsome G; McBride BJ; Griffiths GL; Hansen HJ; Goldenberg DM
Cancer Res; 2003 Jan; 63(1):111-8. PubMed ID: 12517786
[TBL] [Abstract][Full Text] [Related]
24. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.
Safavy A; Khazaeli MB; Safavy K; Mayo MS; Buchsbaum DJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333
[TBL] [Abstract][Full Text] [Related]
25. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
Scott CF; Goldmacher VS; Lambert JM; Jackson JV; McIntyre GD
J Natl Cancer Inst; 1987 Nov; 79(5):1163-72. PubMed ID: 3500356
[TBL] [Abstract][Full Text] [Related]
26. Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN.
Visser GW; Klok RP; Gebbinck JW; ter Linden T; van Dongen GA; Molthoff CF
J Nucl Med; 2001 Mar; 42(3):509-19. PubMed ID: 11337531
[TBL] [Abstract][Full Text] [Related]
27. Biodistribution and efficacy of [131I]A33scFv::CDy, a recombinant antibody-enzyme protein for colon cancer.
Panjideh H; Da Silva Coelho VC; Dernedde J; Bachran C; Förster GJ; Franke J; Fasold P; Fuchs H; Thiel E; Deckert PM
Int J Oncol; 2008 Apr; 32(4):925-30. PubMed ID: 18360720
[TBL] [Abstract][Full Text] [Related]
28. Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.
Shankar S; Vaidyanathan G; Kuan CT; Bigner DD; Zalutsky MR
Nucl Med Biol; 2006 Jan; 33(1):101-10. PubMed ID: 16459265
[TBL] [Abstract][Full Text] [Related]
29. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J
Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody.
Kobayashi H; Wu C; Kim MK; Paik CH; Carrasquillo JA; Brechbiel MW
Bioconjug Chem; 1999; 10(1):103-11. PubMed ID: 9893971
[TBL] [Abstract][Full Text] [Related]
31. Improving the tumor retention of radioiodinated antibody: aryl carbohydrate adducts.
Ali SA; Warren SD; Richter KY; Badger CC; Eary JF; Press OW; Krohn KA; Bernstein ID; Nelp WB
Cancer Res; 1990 Feb; 50(3 Suppl):783s-788s. PubMed ID: 2297724
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of iodovinyl antibody conjugates: comparison with a p-iodobenzoyl conjugate and direct radioiodination.
Hadley SW; Wilbur DS
Bioconjug Chem; 1990; 1(2):154-61. PubMed ID: 2095212
[TBL] [Abstract][Full Text] [Related]
33. Non-dehalogenation mechanisms for excretion of radioiodine after administration of labeled antibodies.
De Nardo GL; De Nardo SJ; Miyao NP; Mills SL; Peng JS; O'Grady LF; Epstein AL; Young WC
Int J Biol Markers; 1988; 3(1):1-9. PubMed ID: 3249042
[TBL] [Abstract][Full Text] [Related]
34. Site-specific 99mTc-labeling of antibody using dihydrazinophthalazine (DHZ) conjugation to Fc region of heavy chain.
Jeong JM; Lee J; Paik CH; Kim DK; Lee DS; Chung JK; Lee MC
Arch Pharm Res; 2004 Sep; 27(9):961-7. PubMed ID: 15473668
[TBL] [Abstract][Full Text] [Related]
35. Preparation and biological evaluation of radiolabelled antibodies with selected carbohydrate modifications.
Qi P; Sykes TR; Koganty RR; Selvaraj S; Noujaim AA
Nucl Med Biol; 1993 May; 20(4):453-9. PubMed ID: 8504287
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and radioiodination of tyramine cellobiose for labeling monoclonal antibodies.
Ali SA; Eary JF; Warren SD; Badger CC; Krohn KA
Int J Rad Appl Instrum B; 1988; 15(5):557-61. PubMed ID: 3254878
[TBL] [Abstract][Full Text] [Related]
37. Labeling of monoclonal antibodies with radionuclides.
Bhargava KK; Acharya SA
Semin Nucl Med; 1989 Jul; 19(3):187-201. PubMed ID: 2503873
[TBL] [Abstract][Full Text] [Related]
38. Lysine-directed conjugation of ethidium homodimer to B72.3 antibody: retention of immunoreactivity but altered tumor targeting.
Harapanhalli RS; Matalka KZ; Jones PL; Mahmood A; Adelstein SJ; Kassis AI
Nucl Med Biol; 1998 Apr; 25(3):267-78. PubMed ID: 9620633
[TBL] [Abstract][Full Text] [Related]
39. Development of a model system to evaluate methods for radiolabeling monoclonal antibodies.
Otsuka FL; Welch MJ; McElvany KD; Nicolotti RA; Fleischman JB
J Nucl Med; 1984 Dec; 25(12):1343-9. PubMed ID: 6502256
[TBL] [Abstract][Full Text] [Related]
40. Antigen protection of monoclonal antibodies undergoing labelling.
Ramjeesingh M; Zywulko M; Rothstein A; Whyte R; Shami EY
J Immunol Methods; 1990 Oct; 133(2):159-67. PubMed ID: 2230135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
